Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient’s own T cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. The company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered TIL. The company is led by world-class cell therapy experts and backed by premier global institutional investors. Instil is located in the greater Los Angeles area with additional manufacturing and research facilities in Manchester, UK.
Location: United States
Employees: 201-500
Founded date: 2018
Investors 3
| Date | Name | Website |
| 17.07.2020 | Logos Capi... | logoscapit... |
| - | Vivo Capit... | vivocapita... |
| - | HBM Partne... | hbmpartner... |
Mentions in press and media 9
| Date | Title | Description | Source |
| 31.10.2022 | Instil Bio Announces Voluntary Pause of Enrollment in Ongoin... | Voluntarily paused enrollment in ITIL-168 and ITIL-306 trials pending outcome of manufacturing analy... | globenewsw... |
| 18.10.2022 | Instil Bio Announces First Patient Dosed with ITIL-306, our ... | • ITIL-306 is a novel TIL therapy engineered with our CoStAR platform (CoStAR-TIL) targeting folate ... | globenewsw... |
| 06.09.2022 | Instil Bio Announces Appointment of Tim Moore as Chief Opera... | DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-sta... | globenewsw... |
| 12.08.2022 | Instil Bio Reports Second Quarter 2022 Financial Results and... | Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of ... | globenewsw... |
| 27.05.2022 | Instil Bio Announces IND Clearance of First CoStAR-TIL progr... | FDA granted IND clearance for ITIL-306, Instil’s first genetically-engineered CoStAR-TIL therapy for... | globenewsw... |
| 18.05.2022 | Instil Bio to Present Novel TIL Analytics at American Societ... | DALLAS, May 18, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage... | globenewsw... |
| 16.05.2022 | Instil Bio Reports First Quarter 2022 Financial Results and ... | Targeting completion of enrollment in registrational cohort of DELTA-1 in 2022Presenting preclinical... | globenewsw... |
| 19.03.2021 | Instil Bio’s upsized IPO raises $320M for clinical tests of ... | Instil was able to sell more shares and at a higher price than it initially planned. The Dallas-base... | medcitynew... |
| - | Instil Bio’s upsized IPO raises $320M for clinical tests of ... | The cell therapy technology that underpins Instil Bio has treated fewer than two dozen patients in t... | medcitynew... |